Multicenter cooperative observational study of reactivation of hepatitis B virus caused by anticancer treatments for solid tumors

Multicenter cooperative observational study of reactivation of hepatitis B virus caused by anticancer treatments for solid tumors - HBV surveillance Solid tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005369

Enrollment

300

Registered

2011-04-10

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor patients with seropositivity for HBsAg, or seronegativity for HBsAg and seropositivity for HBcAb and/or HBsAb, receiving first chemotherapy including neoadjuvant and adjuvant chemotherapy.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Solid tumor patients receiving first chemotherapy including neoadjuvant and adjuvant chemotherapy. 2)Patients with high risk of HBV reactivation: 1.Seropositivity for HBsAg 2.Seronegativity for HBsAg and seropositivity for HBcAb and/or HBsAb 3)Written informed consent

Exclusion criteria

Exclusion criteria: 1) During hemodialyis or planning to introuce hemodialyis. 2) Seropositivity to HCVAb 3) Seropositivity for HBsAb only with a history of HBV vaccination 4) Not eligible judged by investigators

Design outcomes

Primary

Measure	Time frame
Incidence rate of HBV reactivation Outcome of the patients in whom the HBV reactivation developed	—

Secondary

Measure	Time frame
Investigation of the background of patients in whom the HBV reactivation developed Difference of outcome of the patients between obedience and non-obedience of Japanese guideline of HBV reactivation	—

Countries

Japan

Contacts

Public ContactMasafumi Ikeda, MD.

National Cancer Center Hospital East HBV surveillance data center

masikeda@east.ncc.go.jp04-7133-1111

Outcome results